Back to top
more

Fresenius Medical Care AG & Co. (FMS)

(Real Time Quote from BATS)

$23.46 USD

23.46
124,652

-0.96 (-3.93%)

Updated Aug 6, 2025 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for October 14th

by Zacks Equity Research

ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.

Zacks Equity Research

Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan

by Zacks Equity Research

Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.

Zacks Equity Research

Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.

Zacks Equity Research

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.

Zacks Equity Research

Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System

by Zacks Equity Research

Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.

Zacks Equity Research

Fresenius Medical's (FMS) Training Center to Boost Patient Care

by Zacks Equity Research

Fresenius Medical (FMS) inaugurates new training center in Korea to help in the improvement of patient care by offering comprehensive education programs for healthcare professionals.

Zacks Equity Research

DaVita's (DVA) Deal to Aid Patients in Kidney Transplantation

by Zacks Equity Research

DaVita (DVA) and NKF collaborate to help kidney patients seeking a living donor, thereby improving health equity in kidney transplant process.

Zacks Equity Research

Fresenius Medical (FMS) Gains 1.1% Since Q1 Earnings Beat

by Zacks Equity Research

Fresenius Medical's (FMS) first-quarter earnings benefit from organic growth in Health Care Products segment, and performance in Asia Pacific.

Zacks Equity Research

DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care

by Zacks Equity Research

DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.

Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics

Zacks Equity Research

Is Fresenius (FMS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Debanjana Dey headshot

4 MedTech Underperformers Poised for a Turnaround in 2021

by Debanjana Dey

Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.

Zacks Equity Research

Is Fresenius (FMS) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Fresenius (FMS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Are Investors Undervaluing Fresenius (FMS) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Retain Fresenius Medical (FMS) Stock

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.

Zacks Equity Research

Is Fresenius Medical Care (FMS) a Good Stock to Pick Now?

by Zacks Equity Research

Is Fresenius Medical Care (FMS) a great pick from the value investor's perspective right now? Read on to know more.

Zacks Equity Research

Fresenius Medical (FMS) Stock Gains 5.6% on Q3 Earnings Beat

by Zacks Equity Research

Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.

Zacks Equity Research

Here's Why You Should Retain Fresenius Medical Stock Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.

Zacks Equity Research

Should Value Investors Buy Fresenius (FMS) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

FMS vs. SMLR: Which Stock Is the Better Value Option?

by Zacks Equity Research

FMS vs. SMLR: Which Stock Is the Better Value Option?

Zacks Equity Research

The Zacks Analyst Blog Highlights: FMS, HOLX and TMO

by Zacks Equity Research

The Zacks Analyst Blog Highlights: FMS, HOLX and TMO

Trina Mukherjee headshot

3 MedTech Outperformers to Grab Amid September Pullback

by Trina Mukherjee

Let's grab these three stocks that have continued to show tremendous promise despite market volatility resulting from the coronavirus pandemic.

Urmimala Biswas headshot

5 Top PEG-Driven Value Stocks Amid Coronavirus-Led Selloffs

by Urmimala Biswas

While searching for a suitable value investment option, investors are unlikely to consider PEG ratio among a number of other popular value metrics.

Debanjana Dey headshot

Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs

by Debanjana Dey

Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.